The FDA on October 27, 2015 approved IMLYGIC®, a genetically-modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma, recurrent after initial surgery. IMLYGIC® is a product of Amgen, Inc.
Bottom Ad
Advertisement
Subscribe
